Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Clin Chim Acta. 2017 Nov;474:44-53. doi: 10.1016/j.cca.2017.09.007. Epub 2017 Sep 11.
Fatty acid-binding proteins, whose clinical applications have been studied, are a family of proteins that reflect tissue injury. Heart-type fatty acid-binding protein (H-FABP) is a marker of ongoing myocardial damage and useful for early diagnosis of acute myocardial infarction (AMI). In the past decade, compared to other cardiac enzymes, H-FABP has shown more promise as an early detection marker for AMI. However, the role of H-FABP is being re-examined due to recent refinement in the search for newer biomarkers, and greater understanding of the role of high-sensitivity troponin. We discuss the current role of H-FABP as an early marker for AMI in the era of high sensitive troponin. H-FABP is highlighted as a prognostic marker for a broad spectrum of fatal diseases, viz., AMI, heart failure, arrhythmia, and pulmonary embolism that could be associated with poor clinical outcomes. Because the cut-off value of what constitutes an abnormal H-FABP potentially differs for each cardiovascular event and depends on the clinical setting, an optimal cut-off value has not been clearly established. Of note, several factors such as age, gender, and cardiovascular risk factors, which affect H-FABP levels need to be considered in this context. In this review, we discuss the clinical applications of H-FABP as a prognostic marker in various clinical settings.
脂肪酸结合蛋白是一类反映组织损伤的蛋白质，其临床应用已得到研究。心脏型脂肪酸结合蛋白（H-FABP）是正在发生的心肌损伤的标志物，有助于急性心肌梗死（AMI）的早期诊断。在过去十年中，与其他心肌酶相比，H-FABP 作为 AMI 的早期检测标志物显示出更大的潜力。然而，由于最近对新型生物标志物的探索以及对高敏肌钙蛋白作用的认识不断加深，H-FABP 的作用正在重新评估。我们讨论了在高敏肌钙蛋白时代 H-FABP 作为 AMI 早期标志物的当前作用。H-FABP 被强调为广泛致命疾病（如 AMI、心力衰竭、心律失常和肺栓塞）的预后标志物，这些疾病可能与不良临床结局相关。由于构成异常 H-FABP 的临界值可能因每个心血管事件而异，并取决于临床环境，因此尚未明确确定最佳临界值。值得注意的是，在这种情况下，需要考虑影响 H-FABP 水平的几个因素，如年龄、性别和心血管危险因素。在这篇综述中，我们讨论了 H-FABP 在各种临床环境中作为预后标志物的临床应用。
